Heron Therapeutics | HRTX - Interest Expense On Debt


Heron Therapeutics reported $600K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Eisai JPY 1.55B 117M Mar/2026
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.08M 517K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 479M 67M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.7M 193K Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Surmodics USD 884K 5K Sep/2024
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Veracyte USD 2K 1000 Dec/2023
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025